Condition: Pancreas Cancer · Locally Advanced · Locally Advanced Pancreatic Adenocarcinoma · Sponsor: Baptist Health South Florida
The purpose of this clinical trial is to determine whether using chemotherapy followed by stereotactic ablative body radiation therapy (SABR) and tumor treating fields (TTF) will slow tumor growth in people with locally advanced pancreas cancer. All participants will receive SABR therapy once per day for five days and use the TTF system for at least 18 hours per day starting on the first day of SABR until the tumor progresses or severe toxicity develops.
This description comes directly from the study's public registry record.
Michael Chuong, M.D. · (786) 596-2000 · MichaelChu@baptisthealth.net
Carla Salazar · (786) 595-7073 · Carla.SalazarMonteagudo@baptisthealth.net
Always discuss trial participation with your own doctor first.
| Miami Cancer Institute at Baptist Health, Inc. | Miami, Florida, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05679674